Iptacopan治疗特发性免疫复合物介导的膜增生性肾小球肾炎:APPARENT多中心随机3期研究方案
APPARENT研究是一项随机、双盲、安慰剂对照3期试验,计划纳入至多68例12至60岁活检确诊的特发性免疫复合物介导的膜增生性肾小球肾炎患者,评估口服补体旁路途径抑制剂iptacopan减少蛋白尿的疗效与安全性。
要点
- Iptacopan是一种口服高效近端补体抑制剂,特异性结合因子B并抑制旁路途径。
- 主要终点为6个月时24小时尿蛋白肌酐比值(UPCR)较基线的变化。
- 患者随机1:1接受iptacopan 200 mg每日两次或安慰剂治疗6个月,随后开放标签治疗6个月。
核心结论
- 本研究将为iptacopan治疗特发性(原发性)免疫复合物介导的膜增生性肾小球肾炎提供疗效和安全性证据。
研究设计与样本
- 随机、双盲、安慰剂对照3期研究(APPARENT;NCT05755386),计划纳入至多68例患者(至少10例青少年),年龄12至60岁,活检确诊为免疫复合物介导的膜增生性肾小球肾炎,蛋白尿≥1 g/g,估算肾小球滤过率(eGFR)≥30 ml/min/1.73 m2。
主要发现
- 所有患者将接受最大耐受剂量的血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂和针对荚膜细菌的疫苗接种。
- 排除任何器官移植、进展性新月体性肾小球肾炎或肾活检显示间质纤维化/肾小管萎缩>50%的患者。
- 患者随机1:1接受iptacopan 200 mg每日两次或安慰剂治疗6个月,随后所有患者开放标签接受iptacopan 200 mg每日两次治疗6个月。
- 主要目的是评估iptacopan与安慰剂相比在6个月时减少蛋白尿(24小时尿蛋白肌酐比值,UPCR)的疗效。
- 关键次要终点将评估eGFR测量的肾功能、达到蛋白尿-eGFR复合终点的患者以及患者报告的疲劳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is an ultra-rare, fast-progressing kidney disease that may be idiopathic (primary) or secondary to chronic infection, autoimmune disorders, or monoclonal gammopathies. Dysregulation of the alternative complement pathway is implicated in the pathophysiology of IC-MPGN; and currently, there are no approved targeted treatments. Iptacopan is an oral, highly potent proximal complement inhibitor that specifically binds to factor B and inhibits the alternative pathway (AP). METHODS: This randomized, double-blind, placebo-controlled phase 3 study (APPARENT; NCT05755386) will evaluate the efficacy and safety of iptacopan in patients with idiopathic (primary) IC-MPGN, enrolling up to 68 patients (minimum of 10 adolescents) aged 12 to 60 years with biopsy-confirmed IC-MPGN, proteinuria ≥1 g/g, and estimated glomerular filtration rate (eGFR) ≥30 ml/min per 1.73 m2. All patients will receive maximally tolerated angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and vaccination against encapsulated bacteria. Patients with any organ transplant, progressive crescentic glomerulonephritis, or kidney biopsy with >50% interstitial fibrosis/tubular atrophy, will be excluded. Patients will be randomized 1:1 to receive either iptacopan 200 mg twice daily (bid) or placebo for 6 months, followed by open-label treatment with iptacopan 200 mg bid for all patients for 6 months. The primary objective of the study is to evaluate the efficacy of iptacopan versus placebo in proteinuria reduction measured as urine protein-to-creatinine ratio (UPCR) (24-h urine) at 6 months. Key secondary end points will assess kidney function measured by eGFR, patients who achieve a proteinuria-eGFR composite end point, and patient-reported fatigue. CONCLUSION: This study will provide evidence toward the efficacy and safety of iptacopan in idiopathic (primary) IC-MPGN.
引用
- Vivarelli M, Bomback AS, Meier M, et al. Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study. Kidney Int Rep. 2023. PMID: 38312795. doi:10.1016/j.ekir.2023.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。